| 000 | 01800 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518013437.0 | ||
| 264 | 0 | _c20200527 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1097-0347 | ||
| 024 | 7 |
_a10.1002/hed.25440 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeizaei, Kaweh | |
| 245 | 0 | 0 |
_aReceptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC. _h[electronic resource] |
| 260 |
_bHead & neck _c01 2019 |
||
| 300 |
_a208-215 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aCrizotinib _xpharmacology |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aHead and Neck Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xpharmacology |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-met _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSorafenib _xpharmacology |
| 650 | 0 | 4 |
_aSulfonamides _xpharmacology |
| 700 | 1 | _aGleißner, Lisa | |
| 700 | 1 | _aHoffer, Konstantin | |
| 700 | 1 | _aBußmann, Lara | |
| 700 | 1 | _aVu, Anh Thu | |
| 700 | 1 | _aSteinmeister, Leonhard | |
| 700 | 1 | _aLaban, Simon | |
| 700 | 1 | _aMöckelmann, Nikolaus | |
| 700 | 1 | _aMünscher, Adrian | |
| 700 | 1 | _aPetersen, Cordula | |
| 700 | 1 | _aRothkamm, Kai | |
| 700 | 1 | _aKriegs, Malte | |
| 773 | 0 |
_tHead & neck _gvol. 41 _gno. 1 _gp. 208-215 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/hed.25440 _zAvailable from publisher's website |
| 999 |
_c29165708 _d29165708 |
||